212 related articles for article (PubMed ID: 37164395)
1. Preventive Inflammation Management with Steroids before Retreatment with Anti-VEGF after Severe Inflammation due to Brolucizumab.
Karmy BE; Castro DG; Ambresin A
Klin Monbl Augenheilkd; 2023 Apr; 240(4):556-562. PubMed ID: 37164395
[TBL] [Abstract][Full Text] [Related]
2. Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab.
Cho H; Shah CP; Weber M; Heier JS
Br J Ophthalmol; 2013 Aug; 97(8):1032-5. PubMed ID: 23766432
[TBL] [Abstract][Full Text] [Related]
3. Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis.
Yu JS; Carlton R; Agashivala N; Hassan T; Wykoff CC
J Manag Care Spec Pharm; 2021 Jun; 27(6):743-752. PubMed ID: 34057392
[No Abstract] [Full Text] [Related]
4. Early Experience With Brolucizumab Treatment of Neovascular Age-Related Macular Degeneration.
Enríquez AB; Baumal CR; Crane AM; Witkin AJ; Lally DR; Liang MC; Enríquez JR; Eichenbaum DA
JAMA Ophthalmol; 2021 Apr; 139(4):441-448. PubMed ID: 33630045
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Time to Retreatment and Visual Function Between Ranibizumab and Aflibercept in Age-Related Macular Degeneration.
Inoue M; Yamane S; Sato S; Sakamaki K; Arakawa A; Kadonosono K
Am J Ophthalmol; 2016 Sep; 169():95-103. PubMed ID: 27320059
[TBL] [Abstract][Full Text] [Related]
6. The combination therapy of subtenon triamcinolone acetonide injection and intravitreal brolucizumab for brolucizumab-related intraocular inflammation.
Shigemoto Y; Sakurada Y; Fukuda Y; Matsubara M; Parikh R; Kashiwagi K
Medicine (Baltimore); 2021 Oct; 100(42):e27580. PubMed ID: 34678906
[TBL] [Abstract][Full Text] [Related]
7. Brolucizumab-related retinal vasculitis with exacerbation following ranibizumab retreatment: A clinicopathologic case study.
Iyer PG; Peden MC; Suñer IJ; Patel N; Dubovy SR; Albini TA
Am J Ophthalmol Case Rep; 2020 Dec; 20():100989. PubMed ID: 33294727
[TBL] [Abstract][Full Text] [Related]
8. MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid.
Khanani AM; Brown DM; Jaffe GJ; Wykoff CC; Adiguzel E; Wong R; Meng X; Heier JS;
Ophthalmology; 2022 Sep; 129(9):974-985. PubMed ID: 35537533
[TBL] [Abstract][Full Text] [Related]
9. Case Report: Acute Retinal Necrosis after Intravitreal Ranibizumab for Exudative Macular Degeneration.
Pan Y; Huang X; Wu Z; Lu S; Chen T; Zou W
Optom Vis Sci; 2021 Mar; 98(3):206-211. PubMed ID: 33633018
[TBL] [Abstract][Full Text] [Related]
10. Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial).
Wykoff CC; Brown DM; Maldonado ME; Croft DE
Br J Ophthalmol; 2014 Jul; 98(7):951-5. PubMed ID: 24518078
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal aflibercept for ranibizumab-resistant exudative age-related macular degeneration with choroidal vascular hyperpermeability.
Nomura Y; Yanagi Y
Jpn J Ophthalmol; 2015 Jul; 59(4):261-5. PubMed ID: 25983109
[TBL] [Abstract][Full Text] [Related]
12. Disease stability and extended dosing under anti-VEGF treatment of exudative age-related macular degeneration (AMD) - a meta-analysis.
Garweg JG; Gerhardt C
Graefes Arch Clin Exp Ophthalmol; 2021 Aug; 259(8):2181-2192. PubMed ID: 33528645
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of brolucizumab in age-related macular degeneration: A systematic review of real-world studies.
Baumal CR; Sørensen TL; Karcher H; Freitas RL; Becher A; Balez S; Clemens A; Singer M; Kodjikian L
Acta Ophthalmol; 2023 Mar; 101(2):123-139. PubMed ID: 36117281
[TBL] [Abstract][Full Text] [Related]
14. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab.
Bakall B; Folk JC; Boldt HC; Sohn EH; Stone EM; Russell SR; Mahajan VB
Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500
[TBL] [Abstract][Full Text] [Related]
15. Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial.
Dugel PU; Jaffe GJ; Sallstig P; Warburton J; Weichselberger A; Wieland M; Singerman L
Ophthalmology; 2017 Sep; 124(9):1296-1304. PubMed ID: 28551167
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.
Heier JS; Brown DM; Chong V; Korobelnik JF; Kaiser PK; Nguyen QD; Kirchhof B; Ho A; Ogura Y; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Soo Y; Anderesi M; Groetzbach G; Sommerauer B; Sandbrink R; Simader C; Schmidt-Erfurth U;
Ophthalmology; 2012 Dec; 119(12):2537-48. PubMed ID: 23084240
[TBL] [Abstract][Full Text] [Related]
17. Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER.
Monés J; Srivastava SK; Jaffe GJ; Tadayoni R; Albini TA; Kaiser PK; Holz FG; Korobelnik JF; Kim IK; Pruente C; Murray TG; Heier JS
Ophthalmology; 2021 Jul; 128(7):1050-1059. PubMed ID: 33207259
[TBL] [Abstract][Full Text] [Related]
18. Seven-year outcomes following intensive anti-vascular endothelial growth factor therapy in patients with exudative age-related macular degeneration.
Lukacs R; Schneider M; Nagy ZZ; Sandor GL; Kaan K; Asztalos A; Enyedi L; Pek G; Barcsay G; Szabo A; Borbandy A; Kovacs I; Resch MD; Papp A
BMC Ophthalmol; 2023 Mar; 23(1):110. PubMed ID: 36932356
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of outer retinal tubulations in eyes switched from intravitreal ranibizumab to aflibercept for treatment of exudative age-related macular degeneration.
Massamba N; Dirani A; Butel N; Fardeau C; Bodaghi B; Ingram A; Lehoang P
Graefes Arch Clin Exp Ophthalmol; 2017 Jan; 255(1):61-67. PubMed ID: 27397583
[TBL] [Abstract][Full Text] [Related]
20. Short-term outcomes of switching to brolucizumab in japanese patients with neovascular age-related macular degeneration.
Kitajima Y; Maruyama-Inoue M; Ikeda S; Ito A; Inoue T; Yanagi Y; Kadonosono K
Jpn J Ophthalmol; 2022 Nov; 66(6):511-517. PubMed ID: 36149566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
